About Us - CiRC Biosciences

CiRC Biosciences

CiRC is developing cellular reprogramming therapies for degenerative diseases. Current treatment options for many of these conditions cannot restore function.

In preclinical development, CiRC generated photoreceptor and dopaminergic neuron precursor cells with the potential to treat a wide range of degenerative diseases. The platform can generate multiple cell types using small molecules and growth factors to transform fibroblasts into needed cells.

CiRC is a Paragon Biosciences portfolio company.

View available career opportunities here

CiRC Biosciences

CiRC is developing cellular reprogramming therapies for degenerative eye and brain diseases. Current treatment options for many of these conditions cannot restore function.

In preclinical development, CiRC generated photoreceptor and dopaminergic neuron precursor cells with the potential to treat a wide range of degenerative diseases. The platform can generate multiple cell types using small molecules and growth factors to transform fibroblasts into needed cells.

CiRC is a Paragon Biosciences portfolio company.

View available career opportunities here

Neurology

Cell replacement therapy holds promise for patients with advanced Parkinson’s disease and certain types of refractory epilepsies. In Parkinson’s disease, dopaminergic neuron cell death leads to a loss of motor function for the 1 million Americans who have no options to halt or reverse the disease. Patients with certain types of epilepsy caused by the loss of GABAergic neurons also lack treatment options.

Ophthalmology

Ophthalmology

CiRC’s platform can potentially alter the trajectory of vision loss for patients with degenerative retinal diseases. Retinitis pigmentosa and geographic atrophy affect approximately five million patients in the United States who have very limited treatment options.

Neurology

CiRC Biosciences

CiRC is developing cellular reprogramming therapies for degenerative eye and brain diseases. Current treatment options for many of these conditions cannot restore function.

In preclinical development, CiRC generated photoreceptor and dopaminergic neuron precursor cells with the potential to treat a wide range of degenerative diseases. The platform can generate multiple cell types using small molecules and growth factors to transform fibroblasts into needed cells.

CiRC is a Paragon Biosciences portfolio company.

Neurology

Cell replacement therapy holds promise for patients with advanced Parkinson’s disease and certain types of refractory epilepsies. In Parkinson’s disease, dopaminergic neuron cell death leads to a loss of motor function for the 1 million Americans who have no options to halt or reverse the disease. Patients with certain types of epilepsy caused by the loss of GABAergic neurons also lack treatment options.

Ophthalmology

Ophthalmology

CiRC’s platform can potentially alter the trajectory of vision loss for patients with degenerative retinal diseases. Retinitis pigmentosa and geographic atrophy affect approximately five million patients in the United States who have very limited treatment options.

Neurology

Neurology

Cell replacement therapy holds promise for patients with advanced Parkinson’s disease and certain types of refractory epilepsies. In Parkinson’s disease, dopaminergic neuron cell death leads to a loss of motor function for the 1 million Americans who have no options to halt or reverse the disease. Patients with certain types of epilepsy caused by the loss of GABAergic neurons also lack treatment options.

Ophthalmology

Neurology

Ophthalmology

CiRC’s platform can potentially alter the trajectory of vision loss for patients with degenerative retinal diseases. Retinitis pigmentosa and geographic atrophy affect approximately five million patients in the United States who have very limited treatment options.